Analyst Research

Report Title Price
Provider: S&P Capital IQ Factual Report
$150.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Seattle Genetics Inc Announces Data From ASG-5ME Phase I Clinical Trial For Pancreatic Cancer


Friday, 25 Jan 2013 09:00am EST 

Seattle Genetics Inc announced that it presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by Seattle Genetics and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of solid tumors. The phase I data from the ASG-5ME clinical trial in advanced pancreatic cancer identified the maximum tolerated dose (MTD) for weekly administration, demonstrated tolerability and provided preliminary evidence for antitumor activity. Key findings included: The MTD was identified as 1.2 mg/kg weekly. Of the 35 patients who participated in the trial at the time of analysis, 18 were treated at the MTD. response for the 18 patients treated at 1.2 mg/kg weekly included one patient (6%) who achieved a partial response, six patients (33%) with stable disease and four patients (22%) who had progressive disease. Seven patients (39%) were not evaluable for response. The most common adverse events occurring in patients at the MTD included fatigue (50.0%), vomiting (44.4%), decreased appetite (38.9%), abdominal pain (33.3%) and nausea (33.3%). 

Company Quote

37.4
1.07 +2.95%
11 Jul 2014